Differential informativeness of serum oncomarkers for detection of rare forms of uterine cancer
https://doi.org/10.25789/YMJ.2022.79.02
Abstract
Aim. The aim of the study was to conduct a comparative analysis of the preoperative level of the concentration of tumor markers CA-125, HE4 and DJ-1 in the blood serum in endometrial and non-endometrial cancer of the uterine body.
Materials and methods. 249 patients with endometrial carcinoma (EC), 33 patients with serous (SC) and 24 patients with clear cell carcinoma (CCC) of the uterine body of stages IIIV according to FIGO were examined. Prior to the start of specialized antitumor treatment, the concentration of CA-125, HE4 and DJ-1 proteins was determined in blood serum by enzyme immunoassay.
Results. In patients with EC, SC and CCC the blood levels of CA-125 and HE4 tumor markers were elevated relative to the reference normal range, but did not differ significantly between the groups (p>0,05). A comparative analysis showed that a statistically significant difference between the groups was found only for the DJ-1 marker. In patients with EC, the mean blood level of DJ-1 corresponded to 521,4±12,8 pg/ml and in rare forms of uterine body cancer it was higher. With CCC the concentration DJ-1 was 984,2±19,2 pg/ml and in SC – 998,5±23,7 pg/ml.
Conclusion. For the differential diagnosis of endometrial and non-endometrial cancer of the body of the uterus, preoperative measurement of the concentration of DJ-1 in the blood is informative.
About the Authors
O. I. Kit
Federal State Budgetary Institution "National Medical Research Center of Oncology" of the Ministry of Health of Russia
Russian Federation
Russian Federation
Kit Oleg Ivanovich – Doctor of Medical Sciences, corresponding member of the Russian Academy of Sciences, Professor, Director General of the Federal State Budgetary Institution "National Medical Research Center of Oncology" of the Ministry of Health of Russia
N. V. Kovalenko
Volgograd Regional Clinical Oncology Center
Russian Federation
Russian Federation
Kovalenko Nadezhda Vitalievna – Candidate of Medical Sciences, Chief Physician
Volgograd
A. Yu. Maksimov
National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Maksimov Alexey Yurievich – Doctor of Medical Sciences, Professor, Deputy General Director
Rostov-on-Don
E. V. Verenikina
National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
Verenikina Ekaterina Vladimirovna – Candidate of Medical Sciences, Head of the Department of Oncogynecology
Rostov-on-Don
S. V. Ryzhkov
Rostov-on-Don City Hospital No. 8”
Russian Federation
Russian Federation
Ryzhkov Sergey Vladimirovich – Candidate of Medical Sciences, Chief Physician
Rostov-on-Don
A. A. Demidova
National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Demidova Aleksandra Aleksandrovna – Candidate of Medical Sciences, Associate Professor, Doctoral Candidate
Rostov-on-Don
References
1. Braun M. M. Diagnosis and Management of Endometrial Cancer / M.M. Braun, E.A. Overbeek-Wager, R.J. Grumbo // Am. Fam. Physician. 2016; 93: 468–474.
2. DJ-1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer / W. Wang, H. Wang, L. Xiang [et al.] // Oncol. Rep. 2020; 44: 77–90. doi: 10.3892/or.2020.7593.
3. DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer / A. Di Cello, M. Di Sanzo, F.M. Perrone [et al.] // Tumor Biol. 2017; 39(6): 1010428317705746. doi: 10.1177/1010428317705746.
4. Failure to recognize preoperatively highrisk endometrial carcinoma is associated with a poor outcome / A. Di Cello, E. Rania, V. Zuccala [et al.] // Eur J Obstet Gynecol Reprod Biol. 2015; 194: 153–160. doi: 10.1016/j.ejogrb.2015.09.004.
5. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients / K. Abbink, P.L. Zusterzeel, A.J. Geurts-Moespot [et al.] // Tumor Biol. 2018; 40(2): 1010428318757103. doi: 10.1177/1010428318757103.
6. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: A multicenter prospective cohort study / C. Reijnen, N.C. Visser, J.C. Kasius [et al.] // J. Gynecol. Oncol. 2019; 30: e70. doi: 10.3802/jgo.2019.30.e70.
7. The clinical significance of DJ-1 and HE4 in patients with endometrial cancer / M. Benati, M. Montagnana, E. Danese [et al.] // J. Clin. Lab. Anal. 2018; 32: e22223. doi: 10.1002/jcla.22223
8. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome / K. Matsuo, N.R. Opper, M.A. Ciccone [et al.] // Obstet Gynecol. 2015; 125: 424–433. doi: 10.1097/AOG.0000000000000636.
Review
For citations:
Kit O.I., Kovalenko N.V., Maksimov A.Yu., Verenikina E.V., Ryzhkov S.V., Demidova A.A. Differential informativeness of serum oncomarkers for detection of rare forms of uterine cancer. Yakut Medical Journal. 2022;(3):8-11. https://doi.org/10.25789/YMJ.2022.79.02
Views:
17
Email this article 